At NextPharma we operate a network of 10 specialised manufacturing sites across Europe, each configured as a centre of excellence for specific dosage forms, technologies or regulatory requirements. Our network covers the full product lifecycle: pharmaceutical development, clinical trial supply, and commercial manufacturing and packaging, all coordinated within a single organisation. Products move between development, clinical and commercial stages without external handoffs, preserving process knowledge, and reducing transfer risk throughout. For a full overview of who we are and how the network is structured, see our company overview.
Commercial manufacturing at NextPharma is delivered through dedicated centres of excellence, each aligned to specific dosage forms and regulatory environments. We cover oral solids, modified release systems, soft capsules, liquids, semi-solids, sterile ophthalmics and otics and high-containment production for hormones, beta-lactams, controlled substances and high potent APIs (HPAPIs) for select dosage forms. Manufacturing is supported by integrated packaging operations at each site, including blistering, bottling, serialisation and secondary packaging.
Our pharmaceutical development capabilities cover formulation, process and analytical development, with direct progression into clinical and commercial manufacturing within the same network. Services include feasibility assessment, dosage form selection, analytical method development, clinical batch manufacture, validation, and stability testing. Because development is performed within the same organisation that supports scale-up and commercial production, external transfers are avoided and process knowledge is preserved from first formulation through to market release.
Our clinical trials services are built around GMP clinical supply, covering IMP manufacturing, packaging, labelling and EU QP release. We coordinate multi-country supply programmes with integrated logistics, comparator sourcing and regulatory support. Manufacturing activities are performed across the network, while packaging and distribution are managed centrally, giving sponsors a single point of accountability from batch manufacture to investigator site delivery.
Our analytical and microbiological capabilities support both development and manufacturing activities across the network, covering method development and validation, stability studies and microbiological testing. These services are integrated within development and commercial programmes and are also available as standalone services for customers requiring independent analytical support.
Our health and nutrition services provide B2B development and manufacturing for food supplement products, including soft capsules (conventional and vegan), solids and liquids for brand owners and retailers. This offering operates within the same manufacturing network, with dedicated capabilities for nutritional products. For brand owners looking to launch without a full development cycle, we offer a catalogue of ready-to-go softgel formulations across a range of health categories.
Tableted pellets
Granules
Capsules
Bi-layer tablets
Sachets
Tablets and capsules in blisters
Tablets and capsules in bottles
Suspensions, emulsions and solutions (aqueous and alcohol-based)
Syrups and double-point ampoule
For a full overview of our sites, visit the NextPharma locations hub.
EMA
FDA
ANVISA
MHRA
PMDA
Whether it's development, manufacturing or supply. Tell us about your project and our experts will get back to you.
